Cell therapy manufacturing is advancing rapidly, but core processing steps remain constrained by shear‑induced damage and open, labor‑intensive workflows. Conventional approaches such as fluidized bed centrifugation and TFF can introduce shear, variability, and operational complexity, increasing risk to cell viability, yield, and scalability. Low-shear, single-use tubular bowl centrifugation enables multiple core unit operations - including harvest, media exchange, washing, seed-train expansion, and pre-formulation - within a closed, automated workflow. Case studies with iPSC aggregates and MSCs demonstrate high viable cell recovery and consistent performance across scales. This scalable approach supports reproducible process development through clinical manufacturing, improving robustness, efficiency, and product quality.